The pre-approval inspection of USFDA was completed successfully with ZERO 483 observation of the manufacturing facilities of Bajaj Healthcare Limited
The company had responded to the agency and carried out the required corrective actions.
The product is expected to be launched by Q4 FY23.
The approval further strengthens the Potassium Chloride franchise for the company.
Strand’s new offering will help people better understand and manage diseases through genomic sequencing
Program will fight the rising incidence of antimicrobial (drug) resistance and improve patient outcomes
Zydus becomes the only Indian oncology player to venture into prognosis and diagnosis along with treatment planning
The show will be a part of the India Pharma Week, a marquee celebration catering to every need of the pharma community attendees
India is home to nearly 80 million diabetics and this number is expected to rise to a staggering 134 million in the next 25 years.
The company registered with REACH Certificate for Ethyl Acetate with a tonnage band of more than 1000 TPA
Subscribe To Our Newsletter & Stay Updated
